Completed PHASE3 INTERVENTIONAL 2-arm NCT03225248

Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia

Multi-center, Randomized, Active-Controlled, Double-Blind, Non-Inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia (MARS Study)

Sponsor: Korea United Pharm. Inc.

Conditions Functional Dyspepsia

Interventions Gasmotin UI05MSP015CT

Updated 5 times since 2017 Last updated: Jul 20, 2017 Started: Nov 5, 2014 Primary completion: Sep 5, 2015 Completion: Oct 12, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03225248, this PHASE3 trial focuses on Functional Dyspepsia and remains completed. Sponsored by Korea United Pharm. Inc., it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Aug 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea United Pharm. Inc.

Data source: Korea United Pharm. Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.